United States
Print page content Print
Increase text size Decrease text size
Text Size
Apoquel Logo

APOQUEL® interrupts the itch cycle, providing dogs fast and safe relief

Apoquel Professional MOA ItchCycle Image
  1. EXPOSURE: Allergens enter via the skin, often due to a disrupted or dysfunctional epidermal barrier1
  2. SENSITIZATION: Allergens are detected by the immune system, priming the immune cells to respond to the allergens in the future1
  3. CYTOKINE RELEASE: Exposure to allergens triggers T-cell activation and the release of itch- and inflammation-causing cytokines such as IL-2, IL-4, IL-6, IL-13 and IL-311
  4. JAK ENZYME ACTIVATION: IL-31 activates peripheral nerves via the JAK-STAT pathway, resulting in transmission of the itch signal to the brain2
  5. ITCH/SCRATCH STIMULATION: The itch signal in the brain triggers scratching and other pruritic behaviors. This, combined with cytokine-induced inflammation, further disrupts the epidermal barrier1,3
  6. EPIDERMAL DAMAGE: The weakened barrier makes the dog more vulnerable to transepidermal allergen entry, thus restarting and perpetuating the cycle of itch1,3
Apoquel MOA playBtn itch cycle video

Indications
Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

Important Safety Information
Do not use APOQUEL in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

References: 1. Marsella R, Sousa CA, Gonzales AJ, et al. Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis. J Am Vet Med Assoc. 2012;241(2):194-207. doi:10.2460/javma.241.2.194. 2. Gonzales AJ, Humphrey WR, Messamore JE, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol. 2013;24(1):48-53. doi:10.1111/j.1365-3164.2012.01098.x. 3. Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol. 2010;21(3):233–248. doi:10.1111/j.1365-3164.2010.00889.x.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

© 2017 Zoetis Services LLC. All rights reserved. APQ-00371